ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Corporation (Ambry), leaders in genetic testing, announced today Tom Schoenherr will serve as Ambry’s new Chief Commercial Officer (CCO). Tom’s primary role will be to build upon Ambry’s success in the genetic testing space following the successful acquisition by Konica Minolta.
Tom Schoenherr brings more than 20 years of commercial experience in molecular diagnostics with a solid track-record for building high-growth companies. Mr. Schoenherr previously led Counsyl's commercial strategy, and was responsible for driving business growth and increasing market share in the very competitive carrier screening space. He also served in similar roles at Quest, Siemens Healthcare and Abbott Diagnostics.
“We are very excited to have Tom on board to lead our commercial team; he brings a great mixture of sales management, leadership and energy,” says Ambry CEO Dr. Aaron Elliott. “In our partnership with Konica Minolta, Ambry is identifying new market opportunities in the pursuit of precision medicine. We believe Tom is the right person to lead that charge.”
As Ambry’s Chief Commercial Officer, Mr. Schoenherr will be responsible for the execution of Ambry’s commercial strategy by overseeing all commercial sales, including business development, client services, genetic specialists and marketing. Mr. Schoenherr will build upon Ambry’s reputation for top quality testing and scientific innovation to lead new market expansion both domestic and globally as a part of Ambry’s growth strategy.
Konica Minolta closed its acquisition of Ambry late October with a mission to combine their existing capabilities in medical imaging, including its high-sensitivity tissue testing immunostaining technology (HSTT), with Ambry’s advanced genetic testing to advance precision medicine.
“We look forward to Tom joining the team to build a commercial organization focused on bringing important research and comprehensive testing to patients,” said Kiyotaka Fujii, President of Global Healthcare, Konica Minolta. “We are certain that the combination of our precise medical imaging, along with Ambry’s expertise in genetic testing will enhance patient care and preserve quality of life.”
“I am excited to be a part of this industry-changing global healthcare dynasty, committed to advancing science and developing breakthrough technologies,” says Mr. Schoenherr. “After pioneering carrier screening at Counsyl, I am excited to propel Ambry to the top of the genetic testing industry.”
Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry is an established leader in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.